J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...
Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...
Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions ...
The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.
A new study published in the International Journal of General Medicine showed that by focusing on mast cells and inflammatory ...
Elanco Receives USDA Approval for Befrena (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis. News release. Elanco Animal Health. December 31, ...
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...
Cerapro is a patented, skin pH-lowering cream approved for the treatment of atopic dermatitis under the European Medical Device Regulation (CE Mark)Product launch targeted for 2026 in six European ...
SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback